[go: up one dir, main page]

MX2013004193A - Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. - Google Patents

Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.

Info

Publication number
MX2013004193A
MX2013004193A MX2013004193A MX2013004193A MX2013004193A MX 2013004193 A MX2013004193 A MX 2013004193A MX 2013004193 A MX2013004193 A MX 2013004193A MX 2013004193 A MX2013004193 A MX 2013004193A MX 2013004193 A MX2013004193 A MX 2013004193A
Authority
MX
Mexico
Prior art keywords
preparation
pyridin
amino
acrylic acid
acid derivatives
Prior art date
Application number
MX2013004193A
Other languages
English (en)
Inventor
Claudius Boehm
Susanne Klein
Bernd Napierski
Christian Sommer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2013004193A publication Critical patent/MX2013004193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para la preparación de derivados de ácido 3-(6-amino-piridin-3-il)-2-acrílico La presente invención se refiere a un procedimiento para la preparación de un compuesto de la fórmula I, (ver Fórmula) que comprende hacer reaccionar un compuesto de la fórmula IV (ver Fórmula) con el compuesto de fórmula VII R15-A2-CHO y a nuevos compuestos intermedios usados en ella.
MX2013004193A 2010-11-11 2011-11-08 Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. MX2013004193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306246 2010-11-11
PCT/EP2011/069603 WO2012062730A1 (en) 2010-11-11 2011-11-08 Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives

Publications (1)

Publication Number Publication Date
MX2013004193A true MX2013004193A (es) 2013-06-05

Family

ID=43901646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004193A MX2013004193A (es) 2010-11-11 2011-11-08 Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.

Country Status (14)

Country Link
US (1) US8940901B2 (es)
EP (1) EP2638016B1 (es)
JP (1) JP2013542235A (es)
KR (1) KR20130130737A (es)
CN (1) CN103201269A (es)
AR (1) AR083818A1 (es)
AU (1) AU2011328263A1 (es)
BR (1) BR112013011244A2 (es)
CA (1) CA2814911A1 (es)
IL (1) IL225680A0 (es)
MX (1) MX2013004193A (es)
RU (1) RU2013126689A (es)
SG (1) SG189420A1 (es)
WO (1) WO2012062730A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145385B2 (en) * 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
CN111349043B (zh) * 2018-12-20 2022-09-27 上海医药工业研究院 用于制备派西尼布的中间体及其制备方法和应用
CN111690699A (zh) * 2020-05-19 2020-09-22 浙江工业大学 一种酶促在线合成3-（吡啶-2-氨基）丙羟肟酸的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
MXPA04005940A (es) 2002-01-22 2004-09-13 Pfizer Acidos 3-(imidazolil)-2-aminopropanoicos.
US20030199523A1 (en) 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
AU2003220896A1 (en) 2002-03-28 2003-11-10 Sumitomo Pharmaceuticals Co., Ltd. Novel heteroaryl compounds
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
CN102216276A (zh) * 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
JPWO2010050525A1 (ja) * 2008-10-29 2012-03-29 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
BRPI1010571A2 (pt) * 2009-05-15 2019-09-24 Sanofi Sa processo para a preparação de um composto útil como um inibidor de tafla.
EP2548872B1 (en) * 2010-03-18 2016-09-28 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative

Also Published As

Publication number Publication date
WO2012062730A1 (en) 2012-05-18
EP2638016B1 (en) 2014-10-01
CA2814911A1 (en) 2012-05-18
SG189420A1 (en) 2013-05-31
AU2011328263A1 (en) 2013-05-30
EP2638016A1 (en) 2013-09-18
US20130245274A1 (en) 2013-09-19
BR112013011244A2 (pt) 2017-10-24
KR20130130737A (ko) 2013-12-02
AR083818A1 (es) 2013-03-27
RU2013126689A (ru) 2014-12-20
US8940901B2 (en) 2015-01-27
CN103201269A (zh) 2013-07-10
IL225680A0 (en) 2013-06-27
JP2013542235A (ja) 2013-11-21

Similar Documents

Publication Publication Date Title
IN2012DN02751A (es)
AU2011232516A8 (en) Chemical compounds
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
GEP20125512B (en) Process for synthesis of agomelatin
IN2014MN01521A (es)
UA101835C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
IN2014DN00144A (es)
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
WO2011157390A3 (en) Process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
MY157304A (en) Process for the preparation of a compound useful as an inhibator of tafia
PH12013500343A1 (en) Production method of intermediate compound for synthesizing medicament
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
MX2014004688A (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2012007834A (es) Derivados de acido carboxilico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
UA106195C2 (ru) Способ синтеза агомелатина
WO2014087208A3 (en) A process of preparing alcaftadine
GB201104203D0 (en) Chemical process
SA112330994B1 (ar) عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً

Legal Events

Date Code Title Description
FA Abandonment or withdrawal